ABN-Oncology is a network of Biobanks across several states coordinated by a central Hub. The Hub provides an access portal to the resources available in each of the Member banks as well as other interlinked banks. It also provides support to address technical, legal/ethical, and managerial issues relevant to human biospecimen repositories within Australia and New Zealand.
Lisa has been a member of the Research Division staff at Peter MacCallum Cancer Centre for over 30 years in various roles. For 8 years she managed the Tissue Bank at Peter Mac, gathering cancer samples from Melbourne patients undergoing surgery and then making the cancer tissue samples available for medical research. She has had extensive experience in establishing and expanding biobank protocols, including design of databases to maintain confidential records and clinical data, and development of clear and informative participant recruitment and consent documentation. Lisa currently manages the lifepool project, a prospective cohort of women established as a resource for breast cancer research. As president of the Australasian Biospecimen Network Association and investigator on the ABN-Oncology project, Lisa has a clear commitment to promoting biobanking as an essential tool in translational research.
Heather was appointed in 1997 as the first national manager of kConFab, the Australasian research consortium for families at high risk of breast, ovarian and prostate cancer. She has managed all project logistics, supervises a total of 20 research nurses, database and laboratory staff and ethic submissions to recruit participants at 32 Australasian sites, established the biospecimen and data bank and overseen the distribution of biospecimens. She has a particular interest in expanding upon a biobanks/cohort translational role by supplying participants, their families and their treating family cancer clinics with clinically significant BRCA, p53 and ATM mutation test results and assisting to recruit eligible participants to new targeted therapies based on their genetic testing profile of either germ-line or somatic mutations. She has also been the main organizer of the joint national familial cancer meeting “Families And Cancer” held annually since 1998 that involves all tumour streams and national and international health professional working in the area of familial cancer.
Anna is the Sydney West Chair in Translational Cancer Research, Sydney Medical School, and has directed the Gynaecological Oncology Research program at Westmead since 1995. She is on the Executive of the Sydney-West Translational Cancer Research Centre (SW-TCRC), which aims to enhance translational research across the Sydney West Cancer Network. She is on the Faculty of the Westmead Millennium Institute and the research focus of her lab is on individualization of ovarian cancer treatment through an understanding of genetic and genomic determinants of treatment response, and on understanding the early events that lead to ovarian cancer.
Prof deFazio completed her undergraduate degree (BSc Hons I) at the University of New South Wales, her PhD at the Ludwig Institute for Cancer Research, University of Sydney (1988), and post-doctoral research at the Garvan Institute in Sydney.
Anna is on the management committee of the Gynaecological Oncology Biobank at Westmead and the management committee of the Australian Ovarian Cancer Study (AOCS), a national molecular epidemiology study on ovarian cancer. She is also a chief investigator for the Australasian Biospecimens Network (ABN-Oncology) and is on the Executive of kConFab.
BAppSc (Biomedical), PhD (UNSW) 1995, FFSc (RCPA). A/Prof Catchpoole has 25 years fulltime laboratory research experience into the molecular basis of paediatric malignancies and has extensive experience with the analysis of gene expression as well as cellular and molecular applications associated with research into acute lymphoblastic leukaemia. Since completing his undergraduate degree in 1987, A/Prof Catchpoole’s scientific achievements and publications have centred on paediatric malignancy, specifically acute lymphoblastic leukaemia and neuroblastoma, as well as cancer prone syndromes in children, namely Beckwith Wiedemann syndrome. A/Prof Catchpoole was appointed Head of the Tumour Bank at The Children’s Hospital at Westmead in 2001 and is one of the founding members of the Australian Biospecimens Network – www.abrn.net .
BSc (Hons), PhD (UQld, 1996). Dr Schmidt’s principal research focus is understanding the determinants of clinical responses to active immunotherapy in patients with advanced cancers. He has been the chief scientific investigator on 6 Phase I – III clinical trials, and has expertise in the development and manufacture of cellular immunotherapies (including GMP), establishing and banking primary cancer cell lines, and monitoring T cell responses in cancer patients. The QIMR Cell Line Bank is based on melanoma and lymphoblastoid cell lines derived from trial patients. The lines have been characterised extensively by a number of researchers, and have found applications in studies of melanoma genetics and response to a variety of drugs.
Jenette Creaney is currently a Senior Research Scientist at Sir Charles Gairdner Hospital and a Professor within the School of Medicine, University of Western Australia. She is a principal investigator of the National Research Centre for Asbestos Related Diseases (NCARD) and is a CI in a Centre of Research Excellence Grant. Her research program into mesothelioma integrates biospecimen collection and laboratory research within a clinical trials framework.
Jenette manages the Mesothelioma tissue bank at Sir Charles Gairdner which collects clinical samples following appropriate consent from patients with various pleural and lung conditions particularly mesothelioma but other asbestos induced diseases as well. Her own research has focussed on the identification and development of biomarkers for mesothelioma.
Kylie has been working in the science and medical research field for over 15 years gaining a myriad of experience across several scientific disciplines. For 12 years, she has worked at the Peter MacCallum Cancer Centre, with a majority of her learning experience being at the Peter Mac Tissue Bank as the Resource enhancement Scientist. This role involved the the collection and linkage of clinical data, as well as the generation of valuable resources from biospecimens collected from consented donors. The role also allowed her to interact, liaise and network with a wide variety of patients, hospital clinicians and researchers. Now the project officer for ABN Oncology, Kylie is responsible for the day to day management of researcher requests and the coordinating and collation of information from ABN-Oncology’s linked biobanks.